Climb Bio (CLYM) Other Working Capital Changes (2022 - 2026)
Climb Bio's (CLYM) quarterly Other Working Capital Changes came in at -$62000.0 in Q1 2026, down 5.08% YoY from -$65321.4 in Q1 2025, and up 70.05% on a QoQ basis from -$207000.0 in Q4 2025.
Analysis
Climb Bio (CLYM) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Climb Bio (CLYM) has 5 years of Other Working Capital Changes data on file, last reported at -$62000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 5.08% year-over-year to -$62000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$210000.0 (up 19.85% YoY) and the FY2025 annual result came in at -$207000.0, up 36.7% from the prior year.
- Other Working Capital Changes improved to -$62000.0 in Q1 2026, from -$207000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $102000.0 in Q2 2024 to a low of -$269000.0 in Q3 2024.
- A 5-year average of -$92937.5 and a median of -$104500.0 in 2023 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes surged 200.0% — and 2025, when it plunged 475.0%.
- Tracing CLYM's Other Working Capital Changes over 5 years: stood at -$91000.0 in 2022, then slipped by 20.88% to -$110000.0 in 2023, then surged by 67.27% to -$36000.0 in 2024, then sank by 475.0% to -$207000.0 in 2025, then surged by 70.05% to -$62000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$62000.0 (Q1 2026), -$207000.0 (Q4 2025), and $59000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67,000.00 |
| Jun 30, 2026 | 67,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | -59,000.00 |
| Sep 30, 2025 | -59,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Mar 31, 2025 | -59,000.00 |
| Mar 31, 2025 | -59,000.00 |
| Dec 31, 2024 | -36,000.00 |
| Dec 31, 2024 | -36,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -125,000.00 |
| Jun 30, 2024 | -125,000.00 |
| Mar 31, 2024 | -124,000.00 |
| Mar 31, 2024 | -124,000.00 |